AstraZeneca has signed an AI-led research agreement with China’s CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2025 investor letter. A copy of ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.